MarketBeat reports consensus rating and price target for Eikon Therapeutics, Inc., alongside rating updates from Cantor Fitzgerald and Manufacturers Life Insurance Company.
1 report, 1 independent
Updated Aug 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat reports consensus rating and price target for Eikon Therapeutics, Inc., alongside rating updates from Cantor Fitzgerald and Manufacturers Life Insurance Company.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
-
MarketBeat
American personal finance blog
Related events
- Cantor Fitzgerald increased its price target and rating for Hyperliquid Strategies, while MarketBeat provided consensus rating data.
- Cantor Fitzgerald raised its price target and rating, while Bank of America adjusted its rating and price target, with MarketBeat aggregating the stock rating data.
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
- Cantor Fitzgerald and Citigroup issued rating updates, while MarketBeat reported research notes on Quince Therapeutics.
- MarketBeat reported on analyst coverage for IONQ, noting that Needham reiterated its buy rating, while Cantor Fitzgerald set a $70.00 price target and reiterated its overweight rating.